Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study
|ClinicalTrials.gov Identifier: NCT01647568|
Recruitment Status : Completed
First Posted : July 23, 2012
Last Update Posted : July 23, 2012
At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy.
Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.
|Condition or disease|
|Post-polypectomy Bleeding Anti-platelet Therapy Colonoscopy|
|Study Type :||Observational|
|Actual Enrollment :||715 participants|
|Observational Model:||Case Control|
|Study Start Date :||December 2009|
|Primary Completion Date :||March 2012|
Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01647568
|United States, Texas|
|Dallas VA Medical Center|
|Dallas, Texas, United States, 75216|